Furthermore, a synthesized hybrid molecule of melatonin and HDAC6 inhibitor showed a remarkable AD-modifying property having significantly higher efficacy compared to a positive control of HDAC6 inhibitor (He et al., 2021). This evidence concerns the gene HDAC6 and Alzheimer disease.